Immunomodulatory effects of anti-estrogenic drugs

Immunomodulatory effects of anti-estrogenic drugs There are substantial experimental, epidemiological and clinical evidences that show that breast cancer pathology is influenced by endogenous estrogens. This knowledge is the foundation upon which endocrine deprivation therapy has been developed as a major modality for the management of breast cancer. Tamoxifen, which functions as a competitive partial agonist-inhibitor of estrogen at its receptor, has been widely used for more than three decades for adjuvant endocrine treatment in breast cancer. Currently, other effective drugs for endocrine therapy include raloxifene, different aromatase inhibitors (particularly third-generation agents) and luteinizing hormone-releasing hormone agonists. In recent years, a growing body of evidence suggests that these drugs can also act as immune modulators by altering the function of various leukocytes and the release of different cytokines. Moreover, there is evidence that anti-estrogens may prove to be beneficial in the treatment or prevention of some autoimmune diseases due to their effects on immune function. However, their immunopharmacological aspects in the present state of knowledge are not precisely comprehensible. Only a clear pathophysiological understanding could lead to an efficient strategy for breast cancer prevention and decrease in the mortality due to this disease. Imunomodulatorni učinak antiestrogenih lijekova Postoje značajni eksperimentalni, epidemiološki i klinički dokazi da na patologiju karcinoma dojke utječu endogeni hormoni. Zbog toga je snižavanje razine hormona najvaž niji način terapije ove bolesti. Već više od tri dekade koristi se tamoksifen, kompetitivni parcijalni agonist-inhibitor receptora za estrogene. U suvremenoj terapiji koriste se još raloksifen, različiti inhibitori aromataze (posebno treća generacija inhibitora) i agonisti hormona za oslobađanje luteinizirajućeg hormona. U posljednje vrijeme sve više činjenica ukazuje na to da ti lijekovi imaju i imunomodulatorni učinak, tj. utječu na funkciju leukocita i oslobađanje različitih citokina. štoviše, postoje dokazi da antiestrogeni lijekovi imaju povoljni učinak na neke autoimune bolesti. Međutim, njihov imunofarmakološ ki učinak nije do kraja objašnjen. Samo potpuno razumijevanje patofizioloških procesa može uroditi učinkovitom strategijom za prevenciju i terapiju te smanjenje mortaliteta od karcinoma dojke.

• Publication year

  2012

• Venue

  Acta Pharmaceutica

• Publication date

  2012-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2478/v10007-012-0012-3PMID 22750814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PHARMACOGENOMICS OF TAMOXIFEN

  2013cited by this paper
• Pharmacogenomics of endocrine therapy in breast cancer

  2013cited by this paper
• Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

  2012cited by this paper
• Inflammation and Increased Aromatase Expression Occur in the Breast Tissue of Obese Women with Breast Cancer

  2011cited by this paper
• Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling

  2011cited by this paper
• Mechanisms of endocrine resistance in breast cancer.

  2011cited by this paper
• Tamoxifen and its new derivatives in cancer research.

  2011cited by this paper
• 2‐D gel electrophoresis‐based proteomic analysis reveals that ormeloxifen induces G0–G1 growth arrest and ERK‐mediated apoptosis in chronic myeloid leukemia cells K562

  2011cited by this paper
• Endocrine therapy of breast cancer.

  2011cited by this paper
• Immunological Therapies Can Relieve Aromatase Inhibitor-Related Joint Symptoms in Breast Cancer Survivors

  2010cited by this paper
• Optimal Adjuvant Endocrine Therapy for Early Breast Cancer

  2010cited by this paper
• Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy

  2010cited by this paper
• [Hormonal treatment in breast cancer].

  2010cited by this paper
• Tamoxifen counteracts the allergic immune response and improves allergen‐induced dermatitis in mice

  2010cited by this paper
• Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer

  2010cited by this paper
• Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.

  2010cited by this paper
• Raloxifene Modulates Estrogen-mediated B Cell Autoreactivity in NZB/W F1 Mice

  2010cited by this paper
• Hormonothérapie du cancer du sein

  2010cited by this paper
• Obesity and breast cancer: status of leptin and adiponectin in pathological processes

  2010cited by this paper
• The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

  2010cited by this paper
• Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer

  2010cited by this paper
• Aromatase research and its clinical significance.

  2010cited by this paper
• Treatment with selective estrogen receptor modulators regulates myelin specific T‐cells and suppresses experimental autoimmune encephalomyelitis

  2009cited by this paper
• Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients

  2009cited by this paper
• Pharmacogenomics of tamoxifen therapy.

  2009cited by this paper
• Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.

  2009cited by this paper
• The effects of tamoxifen on immunity.

  2009cited by this paper
• Luteinizing Hormone-Releasing Hormone Enhances T Cell Recovery following Allogeneic Bone Marrow Transplantation1

  2009cited by this paper
• Chemoprevention of breast cancer.

  2008cited by this paper
• Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.

  2008cited by this paper
• Leuprolide--a GnRH agonist--prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice.

  2008cited by this paper
• Pharmacogenomics of endocrine therapy in breast cancer.

  2008cited by this paper
• Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial

  2008cited by this paper
• The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century.

  2008cited by this paper
• Intratumoral estrogen production in breast carcinoma: significance of aromatase

  2008cited by this paper
• Effect of centchroman on cellular and humoral immunity.

  2007cited by this paper
• Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells

  2007cited by this paper
• Estrogen Receptor Antagonist Fulvestrant (ICI 182,780) Inhibits the Anti-Inflammatory Effect of Glucocorticoids

  2007cited by this paper
• Estrogen Receptor Agonists and Immune System in Ovariectomized Mice

  2006cited by this paper
• Improvement in dermatomyositis rash associated with the use of antiestrogen medication.

  2006cited by this paper
• Faculty Opinions recommendation of The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.

  2006cited by this paper
• Tamoxifen Blocks Estrogen-Induced B Cell Maturation but Not Survival1

  2005cited by this paper
• The Selective Estrogen Receptor Modulators, Tamoxifen and Raloxifene, Impair Dendritic Cell Differentiation and Activation 1

  2005cited by this paper
• Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity.

  2005cited by this paper
• Epidemiological risk factors for breast cancer--a review.

  2005cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen

  2004cited by this paper
• Estrogen Preferentially Promotes the Differentiation of CD11c+ CD11bintermediate Dendritic Cells from Bone Marrow Precursors1

  2004cited by this paper
• Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide

  2004cited by this paper
• Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts

  2003cited by this paper
• Pharmacokinetics of third-generation aromatase inhibitors.

  2003cited by this paper
• The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis.

  2003cited by this paper
• Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies

  2003cited by this paper
• Aminoglutethimide-induced leucopenia in a mouse model: effects of metabolic and structural determinates.

  2003cited by this paper
• Effects of Prostaglandin F2α and Progesterone on the Ability of Bovine Luteal Cells to Stimulate T Lymphocyte Proliferation1

  2003cited by this paper
• Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis.

  2002cited by this paper
• [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].

  2002cited by this paper
• [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].

  2002cited by this paper
• Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

  2002cited by this paper
• Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomised Balb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE).

  2001cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cited by this paper
• Effects of Oestradiol and the Oestrogen Antagonist lei 182,780 on the Delayed Type Hypersensitivity (DTH) Index and on Serum Levels of lgM and lgG in Ovariectomised Balb/C and MRL/Mp-Lpr/Lpr Mice, a Model of Systemic Lupus Erythematosus (SLE)

  2001cited by this paper
• Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells.

  2001cited by this paper
• Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

  2000cited by this paper
• Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice.

  2000cited by this paper
• Antiestrogens affect both pathways of killer cell-mediated oncolysis.

  2000cited by this paper
• The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis.

  2000cited by this paper
• Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL‐lpr/lpr mice

  2000cited by this paper
• Tamoxifen Decreases Renal Inflammation and Alleviates Disease Severity in Autoimmune NZB/W F1 Mice

  2000cited by this paper
• Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.

  2000cited by this paper
• The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis.

  2000cited by this paper
• Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells.

  2000cited by this paper
• Increased Natural Killer Cell Activities in Patients Treated with Gonadotropin Releasing Hormone Agonist

  1999cited by this paper
• Hormonal therapy for breast cancer. An update.

  1999cited by this paper
• Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

  1999cited by this paper
• [Estrogen and breast cancer].

  1999cited by this paper
• Antioestrogens Enhance Tumour Necrosis Factor Receptor 2 (TNF‐R2) Expression and TNF‐R2‐Mediated Proliferation in Activated T Cells

  1998cited by this paper
• Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.

  1997cited by this paper
• The Effect of Anti‐Oestrogens on Cytokine Production In Vitro

  1996cited by this paper
• Natural Cytotoxicity and GnRH Agonist Administration in Advanced Endometriosis: Positive Modulation on Natural Killer Activity

  1996cited by this paper
• Anti‐estrogens enhance the therapeutic effect of lymphokine‐activated killer cells on the P815 murine mastocytoma

  1996cited by this paper
• Estrogen and Breast Cancer

  1996cited by this paper
• The effect of Toremifene on the expression of some genes in human mononuclear cells.

  1995cited by this paper
• Gonadotropin Releasing Hormone (GnRH) Agonist Induces Down‐Regulation of the CD3+CD25+ Lymphocyte Subpopulation in Peripheral Blood

  1995cited by this paper
• The effect of Toremifene on the expression of some genes in human mononuclear cells.

  1995cited by this paper
• Modulation of biological responses of normal human mononuclear cells by antiestrogens.

  1993cited by this paper
• In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer

  1993cited by this paper
• Oestrogens and breast cancer: biological considerations.

  1991cited by this paper
• [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].

  1991cited by this paper
• Influence of adjuvant tamoxifen on blood lymphocytes

  1988cited by this paper
• A double‐blind, placebo‐controlled trial

  1986cited by this paper
• Evidence for the involvement of corticosterone in the ontogeny of the cellular immune apparatus of the mouse.

  1978cited by this paper
• Letter: Woodpecker's tongues.

  1976cited by this paper
• [Hormonal treatment of breast cancer].

  1953cited by this paper
• On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

  1896cited by this paper

• Using hormonotherapy in breast cancer and its relationship with metabolic syndrome

  2024cites this paper
• High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses.

  2024cites this paper
• Can letrozole be repurposed for the treatment of visceral leishmaniasis?

  2024cites this paper
• CD28-signaling can be partially compensated in CD28-knockout mice but is essential for virus elimination in a murine model of multiple sclerosis

  2023cites this paper
• Bullous neutrophilic dermatosis with severe acral oedema post‐COVID‐19 mRNA vaccination

  2022cites this paper
• Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

  2022cites this paper
• Like Brothers in Arms: How Hormonal Stimuli and Changes in the Metabolism Signaling Cooperate, Leading HPV Infection to Drive the Onset of Cervical Cancer

  2022cites this paper
• Anastrozole‐related dermatitis with mainly unilateral distribution

  2022cites this paper
• The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions—Evidence for Estrogen as an Immunomodulator

  2021cites this paper
• Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane.

  2021cites this paper
• Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy

  2020cites this paper
• Post-treatment Hematological Variations and the Role of Hemoglobin as a Predictor of Disease-free Survival in Stage 2 Breast Cancer Patients

  2020cites this paper
• Estrogen receptor alpha gene (ESR1) polymorphism can contribute to clinical findings in systemic lupus erythematosus patients

  2017cites this paper
• Tumor-linked HER2 expression: association with obesity and lipid-related microenvironment

  2017cites this paper
• Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review

  2016influential citation
• Aromatase inhibitors and anti-synthetase syndrome

  2016cites this paper
• Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

  2016cites this paper
• Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation

  2016cites this paper
• Role of G Protein-coupled Orphan Receptors in Intestinal Inflammation: Novel Targets in Inflammatory Bowel Diseases

  2015cites this paper
• Tamoxifen disrupts the immune response of gilthead seabream (Sparus aurata L.)

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCVII. G Protein–Coupled Estrogen Receptor and Its Pharmacologic Modulators

  2015cites this paper
• What have we learned about GPER function in physiology and disease from knockout mice?

  2015cites this paper
• Estrogen biology: new insights into GPER function and clinical opportunities.

  2014cites this paper
• The Immunoendocrine Network in Breast Cancer

  2014cites this paper
• Small Circular DNAs in Human Pathology Stephany

  2014cites this paper
• Small Circular DNAs in Human Pathology.

  2014cites this paper
• Pathobiology of cancer and clinical biochemistry

  2013cites this paper
• The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions — Evidence for Estrogen as an Immunomodulator

  year unknowncites this paper